A fluorescence resonance energy transfer-based binding assay for characterizing kinase inhibitors: Important role for C-terminal biotin tagging of the kinase

Analytical Biochemistry

Volumn 395, Issue 2, 2009, Pages 256-262

  Kwan, Joyce ^a   Ling, Alden ^a   Papp, Eva ^a   Shaw, David ^a   Bradshaw, J Michael ^a  

^a ROCHE BIOSCIENCE   (United States)

Author keywords

Competition binding; Fluorescent assay; FRET; Kinase

Indexed keywords

ACYLATION; AMINO ACIDS; ANTIBODIES; BINDING ENERGY; COENZYMES; ENERGY TRANSFER; ENZYME INHIBITION; PURIFICATION;

FLUORESCENCE RESONANCE ENERGY TRANSFER; FLUORESCENT ASSAYS; FRET; GLUTATHIONE S-TRANSFERASES; KINASE; PROTEIN KINASE INHIBITORS; PURIFICATION TAGS; TIME-RESOLVED FLUORESCENCE;

FORSTER RESONANCE ENERGY TRANSFER;

ADENOSINE DIPHOSPHATE; BIOTIN; DASATINIB; GLUTATHIONE TRANSFERASE; HISTIDINE; PROTEIN ANTIBODY; PROTEIN TYROSINE KINASE; PROTEIN TYROSINE KINASE INHIBITOR; STREPTAVIDIN; TYRPHOSTIN 25; UNCLASSIFIED DRUG;

AMINO TERMINAL SEQUENCE; ARTICLE; BINDING ASSAY; BIOTINYLATION; CARBOXY TERMINAL SEQUENCE; CONTROLLED STUDY; DRUG DETERMINATION; DRUG SYNTHESIS; ENZYME PURIFICATION; FLUORESCENCE RESONANCE ENERGY TRANSFER; NONHUMAN; PRIORITY JOURNAL; PROTEIN PROTEIN INTERACTION;

EID: 70349969567     PISSN: 00032697     EISSN: 10960309     Source Type: Journal    
DOI: 10.1016/j.ab.2009.08.032     Document Type: Article

References (21)

1. Singh P., and Ward W.H.J. Alternative assay formats to identify diverse inhibitors of protein kinases. Expert Opin. Drug Discov. 3 (2008) 819-831
2. Cohen P. Protein kinases: the major drug targets of the twenty-first century?. Nat. Rev. Drug Discov. 1 (2002) 309-315
3. Noble M.E., Endicott J.A., and Johnson L.N. Protein kinase inhibitors: insights into drug design from structure. Science 303 (2004) 1800-1805
4. Chene P. Challenges in design of biochemical assays for the identification of small molecules to target multiple conformations of protein kinases. Drug Discov. Today 13 (2008) 522-529
5. Barr R.K., Boehm I., Attwood P.V., Watt P.M., and Bogoyevitch M.A. The critical features and the mechanism of inhibition of a kinase interaction motif-based peptide inhibitor of JNK. J. Biol. Chem. 279 (2004) 36327-36338
6. Okram B., Nagle A., Adrian F.J., Lee C., Ren P., Wang X., Sim T., Xie Y., Wang X., Xia G., Spraggon G., Warmuth M., Liu Y., and Gray N.S. A general strategy for creating "inactive-conformation" Abl inhibitors. Chem. Biol. 13 (2006) 779-786
7. Bogoyevitch M.A., and Fairlie D.P. A new paradigm for protein kinase inhibition: blocking phosphorylation without directly targeting ATP binding. Drug Discov. Today 12 (2007) 622-633
8. Liu Y., and Gray N.S. Rational design of inhibitors that bind to inactive kinase conformations. Nat. Chem. Biol. 2 (2006) 358-364
9. Lebakken C.S., Hee Chol K., and Vogel K.W. A fluorescence lifetime based binding assay to characterize kinase inhibitors. J. Biomol. Screen. 12 (2007) 828-841
10. Takeda H., Fukumoto A., Miura A., Goshima N., and Nomura N. High-throughput kinase assay based on surface plasmon resonance suitable for native protein substrates. Anal. Biochem. 357 (2006) 262-271
11. Smith C.K., and Windsor W.T. Thermodynamics of nucleotide and non-ATP-competitive inhibitor binding to MEK1 by circular dichroism and isothermal titration calorimetry. Biochemistry 46 (2007) 1358-1367
12. Rich R.L., and Myszka D.G. Higher-throughput, label-free, real-time molecular interaction analysis. Anal. Biochem. 361 (2007) 1-6
13. Zhang W.X., Wang R., Wisniewski D., Marcy A.I., LoGrasso P., Lisnock J.M., Cummings R.T., and Thompson J.E. Time-resolved Förster resonance energy transfer assays for the binding of nucleotide and protein substrates to p38α protein kinase. Anal. Biochem. 343 (2005) 76-83
14. C.S. Labakken, S.M. Riddle, U. Singh, W.J. Frazee, H.C. Eliason, Y. Gao, L.J. Reichling, B.D. Marks, K.W. Vogel, Development and applications of a broad-coverage, TR-FRET-based kinase binding assay platform, J. Biomol. Screen., in press.
15. Tirat A., Freuler F., Stettler T., Mayr L.M., and Leder L. Evaluation of two novel tag-based labelling technologies for site-specific modification of proteins. Int. J. Biol. Macromol. 39 (2006) 66-76
16. Hantschel O., Rix U., Schmidt U., Burckstummer T., Kneidinger M., Schutze G., Colinge J., Bennett K.L., Ellmeier W., Valent P., and Superti-Furga G. The Btk tyrosine kinase is a major target of the Bcr-Abl inhibitor dasatinib. Proc. Natl. Acad. Sci. USA 104 (2007) 13283-13288
17. Dinh M., Grunberger D., Ho H., Tsing S.Y., Shaw D., Lee S., Barnett J., Hill R.J., Swinney D.C., and Bradshaw J.M. Activation mechanism and steady state kinetics of Bruton's tyrosine kinase. J. Biol. Chem. 282 (2007) 8768-8776
18. Mahajan S., Ghosh S., Sudbeck E.A., Zheng Y., Downs S., Hupke M., and Uckun F.M. Rational design and synthesis of a novel anti-leukemic agent targeting Bruton's tyrosine kinase (BTK), LFM-A13 [α-cyano-β-hydroxy-β-methyl-N-(2,5-dibromophenyl)propena mide]. J. Biol. Chem. 274 (1999) 9587-9599
19. Huse M., and Kuriyan J. The conformational plasticity of protein kinases. Cell 109 (2002) 275-282
20. Mol C.D., Fabbro D., and Hosfield D.J. Structural insights into the conformational selectivity of STI-571 and related kinase inhibitors. Curr. Opin. Drug Discov. Dev. 7 (2004) 639-648
21. Lackey K.E. Lessons from the drug discovery of Lapatinib, a dual ErbB1/2 tyrosine kinase inhibitor. Curr. Top. Med. Chem. 6 (2006) 435-460